NZ582056A - Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation - Google Patents

Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation

Info

Publication number
NZ582056A
NZ582056A NZ582056A NZ58205608A NZ582056A NZ 582056 A NZ582056 A NZ 582056A NZ 582056 A NZ582056 A NZ 582056A NZ 58205608 A NZ58205608 A NZ 58205608A NZ 582056 A NZ582056 A NZ 582056A
Authority
NZ
New Zealand
Prior art keywords
carboxamide
indole
compounds
pyrimidin
formula
Prior art date
Application number
NZ582056A
Other languages
English (en)
Inventor
Rajagopal Bakthavatchalam
David C Ihle
Scott M Capitosti
David J Wustrow
Jun Yuan
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NZ582056A publication Critical patent/NZ582056A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ582056A 2007-08-10 2008-08-11 Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation NZ582056A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10
PCT/US2008/072760 WO2009023623A1 (en) 2007-08-10 2008-08-11 Heteroaryl amide analogues

Publications (1)

Publication Number Publication Date
NZ582056A true NZ582056A (en) 2012-08-31

Family

ID=40351102

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ582056A NZ582056A (en) 2007-08-10 2008-08-11 Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation

Country Status (14)

Country Link
EP (1) EP2185560A4 (Direct)
JP (2) JP2010535816A (Direct)
KR (1) KR20100066422A (Direct)
CN (1) CN101778850A (Direct)
AU (1) AU2008286946B2 (Direct)
BR (1) BRPI0812594A2 (Direct)
CA (1) CA2691512A1 (Direct)
CO (1) CO6251319A2 (Direct)
EA (1) EA020332B1 (Direct)
IL (1) IL202550A0 (Direct)
NZ (1) NZ582056A (Direct)
SG (1) SG183699A1 (Direct)
UA (1) UA99729C2 (Direct)
WO (1) WO2009023623A1 (Direct)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2243772E (pt) * 2009-04-14 2012-03-28 Affectis Pharmaceuticals Ag Novos antagonistas de p2x7r e sua utilização
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2724531T3 (es) * 2011-05-12 2019-09-11 Proteostasis Therapeutics Inc Reguladores de proteostasis
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
CA2863228C (en) * 2012-01-20 2020-07-21 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
BR112015013463B1 (pt) 2012-12-12 2022-06-14 Idorsia Pharmaceuticals Ltd Derivados de carboxamida indol como antagonistas do receptor de p2x7
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
WO2014115078A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
EP2956135B1 (en) 2013-01-22 2016-11-16 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2638850T3 (es) 2013-02-19 2017-10-24 Pfizer Inc. Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7調控劑
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
EP3112366B1 (en) 2013-03-14 2018-02-28 Janssen Pharmaceutica NV P2x7 modulators
KR102301753B1 (ko) * 2013-07-17 2021-09-15 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 아자인돌 화합물, 이의 합성, 및 이의 사용 방법
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
EP3191492B1 (en) 2014-09-12 2019-01-09 Janssen Pharmaceutica NV P2x7 modulators
US20180118749A1 (en) 2014-09-12 2018-05-03 Janssen Pharmaceutica Nv P2x7 modulators
JP7055017B2 (ja) 2014-09-29 2022-04-15 武田薬品工業株式会社 結晶形の1-(1-メチル-1h-ピラゾール-4-イル)-n-((1r,5s,7s)-9-メチル-3-オキサ-9-アザビシクロ[3.3.1]ノナン-7-イル)-1h-インドール-3-カルボキサミド
AU2015362700B2 (en) * 2014-12-15 2020-04-16 Merck Patent Gmbh Indole and azaindoles derivatives and their use in neurodegenerative diseases
JP6462493B2 (ja) 2015-05-29 2019-01-30 株式会社デンソー 進入判定装置、進入判定方法
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
JOP20210058A1 (ar) 2018-09-28 2021-03-24 Janssen Pharmaceutica Nv مُعدلات ليباز أُحادِيُّ الجلِيسِريد
CA3111309A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
MX2022011902A (es) 2020-03-26 2023-01-04 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa.
WO2022062991A1 (zh) * 2020-09-22 2022-03-31 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
DE2931323A1 (de) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh Neue n-aminoalkylindol-derivate und ihre salze
DE3131527A1 (de) * 1981-08-08 1983-02-24 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
TW229140B (Direct) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
DE69829879T2 (de) * 1997-12-24 2006-03-02 Sanofi-Aventis Deutschland Gmbh Indolderivate als faktor xa inhibitoren
BR0009651A (pt) * 1999-04-09 2002-01-08 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
DE60039059D1 (de) * 1999-10-07 2008-07-10 Amgen Inc Triazin-kinase-hemmer
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ スクイブ カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US7112594B2 (en) * 2000-08-09 2006-09-26 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
IL160253A0 (en) * 2001-08-09 2004-07-25 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
DK1549638T3 (da) * 2002-10-03 2008-01-21 Hoffmann La Roche Indol-3-carboxamider som glucokinase (GK) aktivatorer
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TW200700387A (en) * 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
CA2643983A1 (en) * 2006-02-21 2007-08-30 Amgen, Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors

Also Published As

Publication number Publication date
EP2185560A1 (en) 2010-05-19
BRPI0812594A2 (pt) 2015-06-23
JP2010535816A (ja) 2010-11-25
IL202550A0 (en) 2010-06-30
JP2015110566A (ja) 2015-06-18
EP2185560A4 (en) 2011-10-05
WO2009023623A1 (en) 2009-02-19
KR20100066422A (ko) 2010-06-17
EA200971085A1 (ru) 2010-06-30
EA020332B1 (ru) 2014-10-30
CN101778850A (zh) 2010-07-14
SG183699A1 (en) 2012-09-27
AU2008286946B2 (en) 2013-11-21
AU2008286946A1 (en) 2009-02-19
UA99729C2 (en) 2012-09-25
CA2691512A1 (en) 2009-02-19
CO6251319A2 (es) 2011-02-21

Similar Documents

Publication Publication Date Title
NZ582056A (en) Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation
NL1026958C2 (nl) Aryl- of heteroarylamideverbindingen.
NL1028947C2 (nl) Gesubstitueerde methylaryl- of heteroarylamideverbindingen.
US10005731B2 (en) Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases
KR101507717B1 (ko) Pde4 억제제로서 유용한 치환된 아세토페논
CN101550114A (zh) 具有cb1拮抗、激动或部分激动活性的噻唑衍生物
NZ573832A (en) N-(4-{ 2-[4-aryl-piperazin-1-yl]ethyl} cyclohexyl)-acetamide derivatives for the treatment of neuropsychiatric disorders
NO20054206L (no) Bifenylderivater
WO2000075113A1 (en) Novel heterocyclic carboxamide derivatives
CA2919948A1 (en) Novel quinazolinones as bromodomain inhibitors
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
ATE486842T1 (de) Substituierte amide
JP2008537741A5 (Direct)
JP2005526798A (ja) 疼痛を治療するためのvr−1受容体修飾因子としてのヘテロ芳香族尿素誘導体
SK4799A3 (en) Use of non-peptidic n3 antagonists for producing pharmaceutical compositions
JP5485391B2 (ja) P2x7調節薬としてのジヒドロピリミドンアミド類
DE60316829D1 (de) Substituierte furoä2,3-büpyridin derivate
EP1437351A1 (en) Amine derivative
JP2010507664A (ja) ベンズイミダゾール化合物
JP2016528274A5 (Direct)
WO2008130616A3 (en) Diaryl morpholines as cb1 modulators
NO20082919L (no) Heteroringsubstituerte 3-alkylazetidinderivater
JP2011519845A5 (Direct)
NZ595797A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
TWI360540B (en) Tetrahydroisoquinolylsulphonamide derivatives, the

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2015 BY SPRUSON + FERGUSON

Effective date: 20130103

LAPS Patent lapsed